Skip to main content
. Author manuscript; available in PMC: 2006 May 30.
Published in final edited form as: J Am Coll Surg. 2004 May;198(5):685–696. doi: 10.1016/j.jamcollsurg.2004.01.025

Table 8.

Clinical Studies in Patients with Melanoma of Active Immunization with the gp100, MART-1, or Tyrosinase Tumor Antigens (12/95-9/03)

Vector n*
Recombinant viruses
Adenovirus 54
Vaccinia 56
Fowlpox 119
Vaccinia+ fowlpox (prime boost) 46
Naked DNA (gp100) 23
Dendritic cells pulsed with peptide 17
Peptides
MART-1 35
gp100 (alone or plus cytokines) 161
Four peptides (gp100 [ 2], MART-1, Tyrosinase) 58
Modified gp100 (210M) and MART-1 (27L) 65
Class II gp100 27
Non-A2 peptides (includes TRP-2) 117
Peptides+ FLT-3 Ligand 7
Peptides + anti-CTLA4 41
Adjuvant immunization, A2 147
Adjuvant immunization, Non-A2 82
Total 1,055

These studies were conducted between December 1995 and September 2003.

*

Some patients received more than one immunizing vector in sequential trials.